Stock listing

NASDAQ:KPRX Kiora Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Kiora Pharmaceuticals, Inc.

Follow Kiora Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:KPRX

$0.72 USD -0.10 (-12.7%)

Close on Nov 20, 2026

Past year -60.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.72 – $0.816 USDNov 20, 2026
Volume
64,687 sharesNov 20, 2026
Market cap
$3.19M USDAt the close on Nov 20, 2026 · price × 4.42M shares outstanding
52-week range
$0.72 – $2.91 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$62,264 USDMedian day 18,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Kiora Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:KPRX · Home$0.72 USD-0.105 (-12.7%)64,687$0.816$0.816$0.72$0.825Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KPRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.72-0.105-12.7%$0.816$0.816$0.7264,687
$0.825-0.105-11.3%$0.93$0.95$0.791118,769
$0.93-0.052-5.3%$0.96$0.981$0.92665,953
$0.982-0.248-20.2%$1.25$1.25$0.95376,034
$1.23-0.10-7.5%$1.36$1.39$1.2088,962
$1.33-0.02-1.5%$1.33$1.39$1.3320,640
$1.35-0.03-2.2%$1.42$1.491$1.3320,500
$1.38-0.13-8.6%$1.51$1.51$1.3722,800
$1.51+0.07+4.9%$1.47$1.56$1.4141,800
$1.44-0.06-4.0%$1.49$1.51$1.4054,300
$1.50-0.16-9.6%$1.68$1.68$1.4852,100
$1.66-0.07-4.0%$1.71$1.74$1.6411,200
$1.73+0.10+6.1%$1.72$1.83$1.6240,500
$1.63+0.07+4.5%$1.65$1.85$1.61270,900
$1.56-0.20-11.4%$1.78$1.825$1.55100,700
$1.76-0.60-25.4%$2.21$2.22$1.73488,700
$2.36+0.06+2.6%$2.32$2.57$2.3229,900
$2.30+0.09+4.1%$2.20$2.31$2.2016,500
$2.21-0.08-3.5%$2.28$2.28$2.2125,000
$2.29-0.03-1.3%$2.32$2.37$2.2424,400
$2.32-0.02-0.9%$2.36$2.36$2.32900
$2.34+0.01+0.4%$2.35$2.37$2.3230,100
$2.33-0.05-2.1%$2.38$2.41$2.3223,500
$2.38-0.02-0.8%$2.37$2.38$2.363,400
$2.40-0.01-0.4%$2.42$2.42$2.3611,900
$2.41-0.06-2.4%$2.46$2.46$2.3525,400
$2.470.000.0%$2.47$2.49$2.4518,300
$2.47-0.09-3.5%$2.55$2.55$2.473,000
$2.56+0.02+0.8%$2.53$2.56$2.5212,800
$2.54+0.01+0.4%$2.515$2.57$2.5154,500
$2.530.000.0%$2.52$2.54$2.4824,300
$2.53+0.03+1.2%$2.51$2.54$2.4921,000
$2.50-0.03-1.2%$2.52$2.62$2.5020,200
$2.53-0.03-1.2%$2.56$2.57$2.528,600
$2.56-0.02-0.8%$2.55$2.56$2.553,400
$2.58+0.02+0.8%$2.57$2.58$2.5616,800
$2.56-0.04-1.5%$2.57$2.57$2.562,400
$2.60-0.07-2.6%$2.63$2.64$2.586,700
$2.67+0.04+1.5%$2.619$2.67$2.6196,700
$2.63-0.04-1.5%$2.623$2.63$2.602,400
$2.67+0.05+1.9%$2.63$2.67$2.5819,400
$2.62-0.09-3.3%$2.73$2.75$2.6210,100
$2.71+0.03+1.1%$2.70$2.80$2.637,600
$2.68-0.08-2.9%$2.75$2.75$2.626,200
$2.76+0.09+3.4%$2.63$2.85$2.6349,300
$2.67+0.07+2.7%$2.65$2.70$2.6320,000
$2.600.000.0%$2.60$2.63$2.5728,500
$2.60-0.05-1.9%$2.66$2.66$2.5919,600
$2.650.000.0%$2.70$2.70$2.60119,000
$2.65+0.07+2.7%$2.59$2.65$2.5910,500
$2.58+0.09+3.6%$2.48$2.58$2.4715,900
$2.49-0.02-0.8%$2.51$2.60$2.4915,800
$2.51-0.04-1.6%$2.64$2.64$2.499,500
$2.550.000.0%$2.58$2.625$2.544,500
$2.55-0.04-1.5%$2.63$2.66$2.553,000
$2.59+0.08+3.2%$2.53$2.64$2.5310,300
$2.510.000.0%$2.54$2.56$2.5014,500
$2.51-0.11-4.2%$2.52$2.555$2.5014,100
$2.62-0.04-1.5%$2.67$2.67$2.622,500
$2.66+0.07+2.7%$2.58$2.72$2.588,700
$2.590.000.0%$2.58$2.592$2.5320,400
$2.59-0.16-5.8%$2.74$2.75$2.5925,244
$2.75+0.09+3.4%$2.65$2.75$2.6511,049
$2.66+0.04+1.5%$2.61$2.66$2.53215,800
$2.62+0.02+0.8%$2.54$2.63$2.549,600

Splits

3 splits since 2019 · NASDAQ:KPRX · every price before a split is adjusted for it

DayRatioWhat
1-for-9Consolidation
1-for-40Consolidation
1-for-15Consolidation
Ticker
NASDAQ:KPRX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Kiora Pharmaceuticals, Inc. news

Kiora Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 83 in all · newest Nov 19, 2026 · oldest 2021
Decks
40 decks · latest Oct 29, 2026

Where Kiora Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:KPRX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:KPRXBOATSUnited StatesUSD
Lang & Schwarz:A40EG5Lang & SchwarzGermanyEUR
Munich:7EYMunichGermanyEUR
Frankfurt:7EYFrankfurtGermanyEUR
gettex:7EYgettexGermanyEUR

Valuation

EV/sales −12.8× against a median of −0.8×: 2nd lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$12.81M USD
P/E
Loss
EV/sales
−12.8×
EV/EBITDA
Negative EBITDA
Price/book
0.2×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.54

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Kiora Pharmaceuticals, Inc. · NASDAQ:KPRXUS$3.19M−US$12.81Mn/a−12.8×n/a0.2×n/a0.0×1.54
Liminatus Pharma, Inc. · NASDAQ:LIMNUS$3.37MUS$1.80Mn/an/an/a11.2×n/a4.8×0.94
Xenetic Biosciences, Inc. · NASDAQ:XBIOUS$3.28M−US$2.53Mn/a−0.8×n/a0.7×−123.7%0.0×1.46
Aprea Therapeutics, Inc. · NASDAQ:APREUS$3.25M−US$34.60Mn/an/an/a0.1×n/a0.0×0.73
Spago Nanomedical AB · OMXSTO:SPAGOUS$3.20MUS$22,063n/a5.6×n/a1.0×n/a0.0×n/a
Azitra Inc · AMEX:AZTRUS$3.13M−US$618,677n/an/an/a0.7×n/a0.0×0.60
NuCana plc · NASDAQ:NCNAUS$3.12M−US$21.37Mn/an/an/a0.1×n/a0.0×1.58
Revive Therapeutics Ltd. · CSE:RVVUS$3.10MUS$3.14Mn/an/an/an/an/an/a0.56
Skye Bioscience, Inc. · NASDAQ:SKYEUS$3.10M−US$1.71Mn/an/an/a2.3×n/a0.0×0.85
Creative Medical Technology Holdings, Inc. · NASDAQ:CELZUS$3.06M−US$3.79Mn/a−1,263×n/a0.4×n/a0.0×1.53
Oncology Pharma Inc. · OTC:ONPHUS$3.04Mn/an/an/an/an/an/an/a1.62
Median of the othersUS$3.13M−US$1.71M−0.8×0.7×−123.7%0.0×0.94

Forecasts

1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
12.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.14 · 1 analyst

Team and board

Officers

OfficerRole
Brian M. StremPresident & Chief Executive Officer
Melissa ToscaChief Financial Officer
Keith J. LaneExecutive Vice President of Clinical Development and Regulatory Affairs
Stefan SperlExecutive Vice President of CMC and Operations

Board

DirectorRole
Praveen TyleChairman
Aron ShapiroDirector
Brian M. StremPresident & Chief Executive Officer
Carmine StengoneDirector
David HollanderDirector
Erin ParsonsDirector
Lisa Walters-HoffertDirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−1.5%
Q2 2026Aug 7, 2026+0.8%
Q1 2026May 8, 2026 · Before open0.0%
Q4 2025Mar 25, 2026−4.4%
Q3 2025Nov 7, 2025 · Before open+0.4%
Q2 2025Aug 8, 2025 · Before open−1.3%
Q1 2025May 9, 2025 · Before open+4.2%
Q4 2024Mar 24, 2025 · Before open−2.7%
Q3 2024Nov 8, 2024 · Before open−1.2%
Q2 2024Aug 9, 2024 · Before open+2.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 10, 2024 · Before open+0.2%
Q4 2023Mar 25, 2024 · Before open−3.2%
Q3 2023Nov 9, 2023 · Before open+3.2%
Q2 2023Aug 8, 2023 · Before open−1.6%
Q1 2023May 9, 2023 · Before open0.0%
Q4 2022Mar 23, 2023 · Before open−9.4%
Q3 2022Nov 9, 2022 · Before open−5.8%
Q2 2022Aug 12, 2022 · Before open−10.4%
Q1 2022Apr 15, 2022 · Before open−5.9%
Q4 2021Mar 2, 2022−5.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck29 slidesOct 29, 2026
Investor Presentation (October 2026)Investor deck29 slidesOct 29, 2026
Investor Presentation (2026)Investor deck24 slides2026
H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (August 2025)Conference25 slidesAug 13, 2025
Investor Presentation (October 2024)Investor deck41 slidesOct 29, 2024
Investor Presentation (February 2024)Investor deck43 slidesFeb 12, 2024
Merger or Acquisition (January 2024)Merger or acquisition19 slidesJan 31, 2024
Investor Presentation (November 2023)Investor deck38 slidesNov 9, 2023
IPO Roadshow (May 2023)IPO roadshow47 slidesMay 15, 2023
Investor Presentation (January 2023)Investor deck28 slidesJan 9, 2023
All 40 decks
DeckKindSlidesDate
IPO Roadshow (July 2022)IPO roadshow34 slidesJul 14, 2022
Investor Presentation (January 2022)Investor deck31 slidesJanuary 2022
Investor Presentation (November 2021)Investor deck26 slidesNovember 2021
EyeGate Pharmaceuticals — Investor Presentation (September 2021)Investor deck30 slidesSep 14, 2021
Eyegate Pharmaceuticals — Investor Presentation (May 2021)Investor deck36 slidesMay 27, 2021
EyeGate Pharmaceuticals — Investor Presentation (September 2020)Investor deck27 slidesSep 14, 2020
EyeGate Pharmaceuticals — Investor Presentation (June 2020)Investor deck28 slidesJun 1, 2020
Eyegate Pharmaceuticals — Investor Presentation (September 2019)Investor deck25 slidesSep 9, 2019
Eyegate Pharmaceuticals — Investor Presentation (December 2018)Investor deck26 slidesDec 12, 2018
Eyegate Pharmaceuticals — Investor Presentation (September 2018)Investor deck22 slidesSep 5, 2018
Eyegate Pharmaceuticals — IPO Roadshow (April 2018)IPO roadshow39 slidesApr 9, 2018
Eyegate Pharmaceuticals — Investor Presentation (March 2018)Investor deck38 slidesMar 12, 2018
Eyegate Pharmaceuticals — Investor Presentation (February 2018)Investor deck14 slidesFeb 26, 2018
Eyegate Pharmaceuticals — Investor Presentation (February 2018)Investor deck33 slidesFeb 12, 2018
Eyegate Pharmaceuticals — Investor Presentation (January 2018)Investor deck30 slidesJan 8, 2018
EyeGate Pharmaceuticals — Investor Presentation (November 2017)Investor deck12 slidesNov 9, 2017
Eyegate Pharmaceuticals — Investor Presentation (September 2017)Investor deck27 slidesSep 12, 2017
Eyegate Pharmaceuticals — IPO Roadshow (May 2017)IPO roadshow29 slidesMay 5, 2017
Eyegate Pharmaceuticals — Investor Presentation (March 2017)Investor deck24 slidesMar 10, 2017
Eyegate Pharmaceuticals — Investor Presentation (January 2017)Investor deck28 slidesJan 30, 2017
Eyegate Pharmaceuticals — Investor Presentation (January 2017)Investor deck23 slidesJan 9, 2017
Eyegate Pharmaceuticals — Investor Presentation (September 2016)Investor deck27 slidesSep 12, 2016
Eyegate Pharmaceuticals — Investor Presentation (June 2016)Investor deck28 slidesJun 1, 2016
Eyegate Pharmaceuticals — Merger or Acquisition (March 2016)Merger or acquisition16 slidesMar 7, 2016
Eyegate Pharmaceuticals — Investor Presentation (January 2016)Investor deck24 slidesJan 19, 2016
Eyegate Pharmaceuticals — Rodman & Renshaw Annual Global Investment Conference 2015Conference24 slidesSep 8, 2015
Eyegate Pharmaceuticals — IPO Roadshow (July 2015)IPO roadshow33 slidesJul 16, 2015
Eyegate Pharmaceuticals — IPO Roadshow (January 2015)IPO roadshow33 slidesJan 16, 2015
Eyegate Pharmaceuticals — IPO Roadshow (October 2014)IPO roadshow37 slidesOct 24, 2014
Eyegate Pharmaceuticals — IPO Roadshow (September 2014)IPO roadshow38 slidesSep 12, 2014

Open Decks

IPO

Went public as EYEGATE PHARMACEUTICALS INC. Priced at US$6.00 a share. Final prospectus filed on Feb 13, 2015.

Price
US$6.00 a share
Shares offered
683,250 shares of common stock
Offering size
US$4.1 million
Underwriters' option
Up to 102,487 more shares
Underwriters
Aegis Capital Corp, Chardan Capital Markets, LLC · In the order on the cover
Shares delivered
On or about Feb 19, 2015

Steps

StepWhen
Draft sent to the SEC in confidenceMay 14, 2014
Filed publiclyJul 30, 2014
Amended 9 timesNewest Feb 4, 2015
Shares registered with an exchangeSep 30, 2014
Declared effective by the SECFeb 12, 2015
Final prospectus, with the priceFeb 13, 2015

Filings

FilingFiled
424B4 · ProspectusFeb 13, 2015
EFFECT · Notice that a registration is effectiveFeb 12, 2015
CORRESP · Letter to the SECFeb 10, 2015
CORRESP · Letter to the SECFeb 10, 2015
8-A12G · Registration of a class of sharesFeb 5, 2015
S-1/A · Registration statement, amendedFeb 4, 2015
S-1/A · Registration statement, amendedJan 26, 2015
CORRESP · Letter to the SECJan 23, 2015
CORRESP · Letter to the SECJan 23, 2015
FWP · Free writing prospectusJan 16, 2015
All 42 filings
FilingFiled
S-1/A · Registration statement, amendedDec 24, 2014
S-1/A · Registration statement, amendedDec 2, 2014
CORRESP · Letter to the SECDec 1, 2014
UPLOAD · Letter from the SECNov 26, 2014
S-1/A · Registration statement, amendedNov 20, 2014
FWP · Free writing prospectusOct 24, 2014
CORRESP · Letter to the SECOct 2, 2014
CORRESP · Letter to the SECOct 2, 2014
CERTNAS · Nasdaq's certificate of listingOct 1, 2014
8-A12B · Registration of shares for listing on an exchangeSep 30, 2014
CORRESP · Letter to the SECSep 30, 2014
CORRESP · Letter to the SECSep 30, 2014
FWP · Free writing prospectusSep 29, 2014
S-1/A · Registration statement, amendedSep 29, 2014
CORRESP · Letter to the SECSep 26, 2014
UPLOAD · Letter from the SECSep 24, 2014
CORRESP · Letter to the SECSep 12, 2014
FWP · Free writing prospectusSep 12, 2014
S-1/A · Registration statement, amendedSep 12, 2014
UPLOAD · Letter from the SECSep 9, 2014
S-1/A · Registration statement, amendedAug 29, 2014
CORRESP · Letter to the SECAug 8, 2014
S-1/A · Registration statement, amendedAug 8, 2014
UPLOAD · Letter from the SECAug 5, 2014
CORRESP · Letter to the SECJul 30, 2014
S-1 · Registration statementJul 30, 2014
UPLOAD · Letter from the SECJul 16, 2014
UPLOAD · Letter from the SECJul 15, 2014
DRS/A · Draft registration statement, amendedJul 8, 2014
DRSLTR · Letter to the SEC with a draftJul 7, 2014
UPLOAD · Letter from the SECJun 12, 2014
DRS · Draft registration statementMay 14, 2014

Open IPO · From the cover of the final prospectus (424B4) filed Feb 13, 2015

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue016.0M00012.1K2.69M1.65M407.5K669.3K
Cost of revenue24.8K379.5K4.03M134.0K227.3K3.27M4.89K8.06M10.3M8.42M
Gross profit-24.8K16.0M-4.03M-134.0K-227.3K-3.26M2.68M-6.40M-9.92M-7.75M
Research and development10.8M7.84M4.03M3.45M5.35M3.57M5.39M8.06M10.3M8.42M
Selling, general and administrative5.75M5.54M4.66M8.28M5.32M4.24M4.41M4.44M4.64M5.59M
Operating income-12.8M4.51M-12.6M-12.3M-14.2M-6.87M-7.00M-10.8M-14.6M-13.3M
Depreciation and amortization24.8K19.2K51.8K41.6K45.3K33.4K51.7K38.5K19.3K5.18K
EBITDA-12.8M4.53M-12.5M-12.3M-14.2M-6.84M-6.95M-10.8M-14.5M-13.3M
Interest expense20.0K21.4K11.1K8.60K6.85K4.19K3251.04K1.22K275
Income before tax-12.1M5.66M-12.4M-13.7M-14.0M-6.85M-7.00M-10.7M-14.6M-13.3M
Income tax-1.28M2.07M90.3K-113.0K-192.6K12.1K95.4K86.0K-1.34M0
Net income-10.8M3.59M-12.5M-13.6M-13.8M-6.86M-7.10M-10.8M-13.2M-13.3M
Earnings per share, basic-2.600.93-24.25-18.55-57.12-1.49-2.23-4.57-0.93-1.51
Earnings per share, diluted-2.640.87-24.25-18.55-57.12-1.49-2.23-4.57-0.93-1.51

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents8.70M3.79M2.45M5.96M7.85M1.19M3.78M8.00M7.81M3.64M
Short-term investments8.39M23.0M0
Receivables1.52M601.2K01.37M529.6K91.0K4.86K18.4K23.7K53.8K
Inventory1
Current assets21.7M29.7M4.74M7.68M8.99M1.73M4.32M8.48M8.46M4.15M
Property, plant and equipment91.7K5.23K8.06K55.2K74.0K30.6K16.8K43.5K55.8K38.0K
Goodwill003.63M1.53M1.53M1.53M5.44M
Total assets24.3M36.5M13.7M18.7M20.1M15.3M10.1M14.3M14.3M9.73M
Accounts payable1.06M415.6K206.3K1.01M160.6K434.8K210.3K63.7K706.1K1.41M
Current liabilities3.63M6.01M1.63M3.27M1.61M1.98M1.41M3.86M14.8M7.31M
Long-term debt278.2K0
Total debt368.3K57.2K106.9K105.8K209.4K278.2K04.71K16.1K28.7K
Total liabilities8.13M10.7M7.60M7.27M5.55M5.57M3.49M5.34M16.2M10.1M
Shareholders' equity16.1M25.8M6.11M11.4M14.6M9.73M6.62M8.94M-1.93M-329.4K
Shares outstanding3.76M3.00M856.2K1.80M316.6K5.56M4.08M3.04M17.3M10.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-9.96M8.56M-9.56M-10.4M-10.7M-7.32M-8.15M-10.8M-6.47M-8.41M
Capital spending-110.8K-6.26K00-63.9K-20.1K0-20.0K-37.0K0
Free cash flow-10.1M8.55M-9.56M-10.4M-10.7M-7.34M-8.15M-10.9M-6.51M-8.41M
Cash from investing14.4M-22.7M06.38K-157.0K-244.4K0-270.0K-37.0K174.7K
Cash from financing265.7K15.5M5.97M8.62M17.6M5.00M3.92M11.3M10.7M3.50M
Dividends paid-7.33K
Share buybacks0-15.6K0-2.61K2.91M
Change in cash4.90M1.34M-3.55M-1.89M6.67M-2.59M-4.23M198.2K4.17M-4.73M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportOct 29, 2026Material contractSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 17, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeSep 17, 2026Big-stake noticeSEC
8-K · Current reportSep 8, 2026Management or board changeSEC
8-K · Current reportAug 19, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 10, 2026Big-stake noticeSEC
8-K · Current reportAug 7, 2026ResultsSEC
10-Q · Quarterly reportAug 7, 2026Quarterly reportSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
8-K · Current reportJun 18, 2026Current reportSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
8-K · Current reportJun 10, 2026Management or board changeSEC
424B3 · ProspectusMay 28, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 26, 2026Other filingsSEC
CORRESP · Letter to the SECMay 20, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 20, 2026Other filingsSEC
S-3 · Registration statementMay 18, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 8, 2026ResultsSEC
10-Q · Quarterly reportMay 8, 2026Quarterly reportSEC
ARS · Annual report to shareholdersMay 1, 2026Annual reportSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
DApr 21, 2026Other filingsSEC
8-K · Current reportApr 7, 2026Material contractSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
8-K · Current reportApr 2, 2026Management or board changeSEC
S-8 · Registration statement for employee plansMar 25, 2026Offer documentSEC
8-K · Current reportMar 25, 2026ResultsSEC
10-K · Annual reportMar 25, 2026Annual reportSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 29, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
8-K · Current reportNov 7, 2025ResultsSEC
10-Q · Quarterly reportNov 7, 2025Quarterly reportSEC
EFFECT · Notice that a registration is effectiveSep 22, 2025Other filingsSEC
CORRESP · Letter to the SECSep 17, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 16, 2025Other filingsSEC
S-3 · Registration statementSep 15, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
8-K · Current reportAug 12, 2025Current reportSEC
8-K · Current reportAug 8, 2025ResultsSEC
10-Q · Quarterly reportAug 8, 2025Quarterly reportSEC
UPLOAD · Letter from the SECJul 1, 2025Other filingsSEC
CORRESP · Letter to the SECJun 20, 2025Other filingsSEC
UPLOAD · Letter from the SECJun 10, 2025Other filingsSEC
8-K · Current reportJun 4, 2025Meeting outcomeSEC
8-K · Current reportJun 3, 2025Material contractSEC
8-K · Current reportMay 9, 2025ResultsSEC
10-Q · Quarterly reportMay 9, 2025Quarterly reportSEC
DEF 14A · Proxy statementApr 30, 2025Meeting noticeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
8-K · Current reportMar 25, 2025ResultsSEC
S-8 · Registration statement for employee plansMar 25, 2025Offer documentSEC
10-K · Annual reportMar 25, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2025Big-stake noticeSEC
8-K · Current reportJan 15, 2025Management or board changeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
8-K · Current reportNov 8, 2024ResultsSEC
10-Q · Quarterly reportNov 8, 2024Quarterly reportSEC
8-K · Current reportOct 29, 2024Current reportSEC
4 · Change in ownershipSep 12, 2024Insider tradeSEC
4 · Change in ownershipSep 11, 2024Insider tradeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
4 · Change in ownershipAug 19, 2024Insider tradeSEC
4 · Change in ownershipAug 15, 2024Insider tradeSEC
8-K · Current reportAug 9, 2024ResultsSEC
10-Q · Quarterly reportAug 9, 2024Quarterly reportSEC
8-K · Current reportJul 30, 2024Current reportSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
4 · Change in ownershipJul 3, 2024Insider tradeSEC
8-K · Current reportJul 1, 2024Management or board changeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
4 · Change in ownershipJun 13, 2024Insider tradeSEC
8-K · Current reportJun 7, 2024Current reportSEC
SC 13G · Big-stake noticeMay 29, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeMay 29, 2024Big-stake noticeSEC
8-K · Current reportMay 10, 2024ResultsSEC
10-Q · Quarterly reportMay 10, 2024Quarterly reportSEC
S-8 · Registration statement for employee plansMay 10, 2024Offer documentSEC
8-K · Current reportMay 2, 2024Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveMar 29, 2024Other filingsSEC
424B3 · ProspectusMar 28, 2024Offer documentSEC
CORRESP · Letter to the SECMar 26, 2024Other filingsSEC
DEF 14A · Proxy statementMar 25, 2024Meeting noticeSEC
8-K · Current reportMar 25, 2024ResultsSEC
10-K · Annual reportMar 25, 2024Annual reportSEC
PRE 14A · Preliminary proxy statementMar 15, 2024Meeting noticeSEC
UPLOAD · Letter from the SECMar 4, 2024Other filingsSEC
S-3 · Registration statementFeb 28, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
DFeb 14, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
8-K · Current reportFeb 12, 2024Current reportSEC
SC 13G · Big-stake noticeFeb 9, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 7, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 6, 2024Big-stake noticeSEC
8-K · Current reportFeb 1, 2024Material contractSEC
8-K · Current reportJan 31, 2024Material contractSEC
8-K · Current reportJan 16, 2024Current reportSEC
8-K · Current reportNov 9, 2023Current reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 6, 2023Current reportSEC
S-8 · Registration statement for employee plansOct 13, 2023Offer documentSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
8-K · Current reportSep 27, 2023Meeting outcomeSEC
8-K · Current reportSep 21, 2023Management or board changeSEC
DEFA14A · Additional proxy materialSep 1, 2023Meeting noticeSEC
8-K · Current reportSep 1, 2023Current reportSEC
3 · Initial statement of ownershipAug 10, 2023Insider tradeSEC
8-K · Current reportAug 8, 2023ResultsSEC
10-Q · Quarterly reportAug 8, 2023Quarterly reportSEC
8-K · Current reportAug 1, 2023Management or board changeSEC
DEF 14A · Proxy statementJul 21, 2023Meeting noticeSEC
8-K · Current reportJul 20, 2023Current reportSEC
PRE 14A · Preliminary proxy statementJul 11, 2023Meeting noticeSEC
8-K · Current reportJun 21, 2023Meeting outcomeSEC
8-K · Current reportJun 15, 2023Material contractSEC
SC 13G · Big-stake noticeJun 13, 2023Big-stake noticeSEC
8-K · Current reportJun 6, 2023Material contractSEC
424B1 · ProspectusJun 2, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 2, 2023Other filingsSEC
CORRESP · Letter to the SECMay 31, 2023Other filingsSEC
CORRESP · Letter to the SECMay 31, 2023Other filingsSEC
S-1/A · Registration statement, amendedMay 31, 2023Offer documentSEC
CORRESP · Letter to the SECMay 24, 2023Other filingsSEC
CORRESP · Letter to the SECMay 24, 2023Other filingsSEC
CORRESP · Letter to the SECMay 23, 2023Other filingsSEC
FWP · Free writing prospectusMay 15, 2023Offer documentSEC
S-1/A · Registration statement, amendedMay 12, 2023Offer documentSEC
UPLOAD · Letter from the SECMay 9, 2023Other filingsSEC
8-K · Current reportMay 9, 2023ResultsSEC
10-Q · Quarterly reportMay 9, 2023Quarterly reportSEC
S-1 · Registration statementMay 5, 2023Offer documentSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
8-K · Current reportApr 27, 2023Current reportSEC
8-K · Current reportMar 30, 2023Current reportSEC
8-K · Current reportMar 23, 2023ResultsSEC
10-K · Annual reportMar 23, 2023Annual reportSEC
4 · Change in ownershipMar 7, 2023Insider tradeSEC
4 · Change in ownershipMar 7, 2023Insider tradeSEC
4 · Change in ownershipMar 7, 2023Insider tradeSEC
4 · Change in ownershipMar 7, 2023Insider tradeSEC

This page holds 200 of 929 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Kiora Pharmaceuticals, Inc.’s releases · as of Nov 10, 2026

Common shares
4,424,387
Fully diluted
4,424,387

Fully diluted

LineSharesAs of
Common shares4,424,387Nov 10, 2026

Share count over time

CountShares
Nov 10, 20264,424,387
Sep 30, 20264,424,387

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Perceptive Advisors LLC438K9.9%US$1.12MSep 30, 2026
Millennium177K4.0%US$453KSep 30, 2026
ADAR1 Capital Management, LLC168K3.8%US$430KSep 30, 2026
Citadel86,7392.0%US$222KSep 30, 2026
Geode Capital46,0831.0%US$118KSep 30, 2026
Two Sigma39,9440.90%US$102KSep 30, 2026
Vanguard39,7040.90%US$102KSep 30, 2026
Renaissance Technologies37,2000.84%US$95,232Sep 30, 2026
Hrt Financial LP16,8730.38%US$43,000Sep 30, 2026
XTX Topco Ltd16,3960.37%US$41,974Sep 30, 2026
All 20 holders
HolderSharesOf the companyValueAs of
Dimensional16,0550.36%US$41,101Sep 30, 2026
LPL Financial LLC12,5000.28%US$32,000Sep 30, 2026
Northern Trust11,7670.27%US$30,124Sep 30, 2026
Caitong International Asset Management Co., Ltd1,6240.04%US$4,157Sep 30, 2026
Tower Research Capital LLC (TRC)7740.02%US$1,981Sep 30, 2026
SBI Securities Co., Ltd.256<0.01%US$655Sep 30, 2026
Pinnacle Financial Group, Inc.250<0.01%US$640Sep 30, 2026
BlackRock58<0.01%US$148Sep 30, 2026
Activest Wealth Management2<0.01%US$5Sep 30, 2026
Citigroup Inc1<0.01%US$3Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund35,9720.81%US$96,405May 31, 2026
Vanguard Extended Market Index Fund19,8610.45%US$52,234Jun 30, 2026
U.S. Vector Equity Portfolio3,9230.09%US$10,278Jul 31, 2026
Dimensional U.S. Core Equity 2 ETF3,5100.08%US$9,196Jul 31, 2026
Fidelity Series Total Market Index Fund3,4460.08%US$9,235May 31, 2026
Omni Small-Cap Value Fund2,0000.05%US$5,260Jun 30, 2026
U.S. Sustainability Core 1 Portfolio1,8950.04%US$4,965Jul 31, 2026
Dimensional US Core Equity 1 ETF1,5740.04%US$4,124Jul 31, 2026
U.S. Social Core Equity 2 Portfolio1,2360.03%US$3,238Jul 31, 2026
Fidelity Total Market Index Fund7470.02%US$2,002May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Nantahala Capital Management, LLC9.99%492KJun 30, 2026Schedule 13G
Perceptive Advisors LLC9.99%442KApr 6, 2026Schedule 13G
ADAR1 Capital Management, LLC9.90%473KJun 30, 2026Schedule 13G
Baselake Partners, LP5.80%258KSep 10, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Peter Greenleaf
Other companies: Pelthos Therapeutics Inc. (Director · Since at least Jul 1, 2025); Aurinia Pharmaceuticals Inc (Chief Executive Officer, Director · Since at least Jan 1, 2021); Antares Pharma Inc (Director · Dec 12, 2018 – May 24, 2022 · Past); BioDelivery Sciences International Inc (Director · May 21, 2018 – Mar 22, 2022 · Past); Avalo Therapeutics, Inc. (Director · Mar 27, 2018 – Aug 7, 2019 · Past); Sucampo Pharmaceuticals Inc (Chief Executive Officer · Sep 30, 2017 – Feb 13, 2018 · Past)
Director · Jul 10, 2018 – Feb 1, 2019 · Past
Steven Boyd
Other companies: Tenax Therapeutics, Inc. (Director · Aug 19, 2020 – May 18, 2022 · Past); Tetraphase Pharmaceuticals Inc (Director · Jan 22, 2020 – Jul 28, 2020 · Past); Vaxart, Inc. (Director · Nov 5, 2019 – Jun 26, 2020 · Past); Aytu BioPharma, Inc. (Director · Apr 18, 2019 – Mar 20, 2021 · Past); Del Frisco's Restaurant Group Inc (Director · Nov 30, 2018 – Nov 30, 2018 · Past); Avalo Therapeutics, Inc. (Director · May 19, 2017 – Mar 10, 2022 · Past)
Director · May 14, 2018 – Jul 27, 2021 · Past
Kenneth L Gayron
Other companies: Research Solutions, Inc (Director · Since at least Dec 4, 2023); Avid Technology Inc (EVP, CFO & Corp Treasurer · Jun 15, 2022 – Nov 7, 2023 · Past)
Director · Mar 3, 2023 – Sep 29, 2023 · Past
Praveen Tyle
Other companies: Skye Bioscience, Inc. (Director · Jul 22, 2021 – Feb 29, 2024 · Past); Lexicon Pharmaceuticals, Inc. (EVP, R&D · Feb 11, 2021 – Feb 28, 2021 · Past)
Director · Since at least Feb 1, 2021
Eric J. Daniels
Other companies: Plus Therapeutics, Inc. (Chief Development Officer · Since at least Apr 9, 2026)
Chief Development Officer · Since at least Oct 21, 2021
Erin Parsons
Other companies: Alimera Sciences Inc (Director · Jan 4, 2023 – Sep 16, 2024 · Past)
Director · Since at least Mar 3, 2023
Aron ShapiroDirector · Since at least Sep 29, 2023
Bernard Malfroy-CamineDirector · Jul 10, 2018 – Feb 1, 2021 · Past
Brian M StremPresident and CEO, Director · Since at least Jul 26, 2021
Brian M. StremPresident & Chief Executive Officer · Since at least Jul 2, 2026
All 19 people
PersonSeat
Carmine StengoneDirector · Since at least Nov 5, 2026
David HollanderDirector · Since at least Nov 5, 2026
Keith J. LaneExecutive Vice President of Clinical Development and Regulatory Affairs · Since at least Sep 8, 2026
Lisa Walters-HoffertDirector · Since at least Nov 5, 2026
Melissa ToscaChief Financial Officer · Since at least Sep 13, 2022
Michael P ManzoVP of Engineering · Feb 28, 2018 – Aug 3, 2021 · Past
Morton GoldbergDirector · Aug 28, 2015 – Feb 1, 2021 · Past
Ryan Randall BrennemanChief Financial Officer · Apr 25, 2016 – Jul 18, 2016 · Past
Stefan SperlExecutive Vice President of CMC and Operations · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Kiora Pharmaceuticals, Inc.